A multi-center randomized, double-blind, parallel group, placebo controlled study, including an additional open label tiotropium group, to assess the efficacy, safety and tolerability of 4 doses of AD 237 inhaled once daily for 28 days in subjects with COPD [chronic obstuctive pulmonary disease],

Trial Profile

A multi-center randomized, double-blind, parallel group, placebo controlled study, including an additional open label tiotropium group, to assess the efficacy, safety and tolerability of 4 doses of AD 237 inhaled once daily for 28 days in subjects with COPD [chronic obstuctive pulmonary disease],

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Sosei R&D
  • Most Recent Events

    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top